Canada's Chromos Molecular Systems and AppTec Laboratory Services
have teamed up to provide the biopharmaceutical industry with a
broader range of cell line engineering and contract manufacturing
The pharmaceutical industry is under pressure from downwards price
pressure, a lack of innovation, and the escalating costs of new
product development, and this is having a knock-on effect for
excipients suppliers. Phil Taylor reports.
Construction of the UK National Biomanufacturing Centre, an
ambitious project aimed at helping biotechnology start-ups get
their product ideas into clinical trials, is progressing on
schedule and should be ready to start production...
The market for low-cost generic drugs looks set to be buoyant for
the foreseeable future, both in Europe as a whole and in France,
according to Hubert Olivier, president of the French subsidiary of
the leading German generics group...
In keeping with the current trend among contract manufacturing
organisations to tap into niche markets, SAFC has started
construction of a new facility aimed at meeting the demand for
manufacturing of highly potent active pharmaceutical...
At the CPhI meeting this year, many contract manufacturing
organisations (CMOs) trumpeted their new investments in capacity,
despite the prevailing wisdom that the pharmaceutical sector is
over-served at present.
Clariant's pharmaceutical fine chemicals business announced a
series of upgrades to its manufacturing facilities around the
world, headed by a new push into contract manufacture of controlled
The challenging environment for companies supplying chemicals into
the pharmaceutical sector, with a relentless increase in
competition, has prompted German company Merck KGaA to start a new
service aimed at reducing the workload...
At the Conference on Pharmaceutical Ingredients (CPhI) opened its
doors yesterday, In-PharmaTechnologist.com spoke with Nick Hyde,
global business director at leading contract manufacturer
Dowpharma, to hear his views on the state...
The predicted deficit in manufacturing capacity for biologic drugs
that has been tipped to impede the development of the market has
not materialised, with capacity exceeding demand, according to new
Overcapacity remains the main issue affecting the European market
for active pharmaceutical ingredients, with lack of capability
differentiation and competition from low-cost manufacturers also
holding back growth in the sector.